The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
Open accessAbstract
Rationale: α v integrins, key regulators of transforming growth factor-β activation and fibrogenesis in in vivo models of pulmonary fibrosis, are expressed on abnormal epithelial cells (α v β 6) and fibroblasts (α v β 1) in fibrotic lungs. Objectives: We evaluated multiple α v integrin inhibition strategies to assess which most effectively reduced fibrogenesis in explanted lung tissue from patients with idiopathic pulmonary fibrosis. Methods: Selective α v β 6 and α v β 1, dual α v β 6/α v β 1, and multi-α v integrin inhibitors were characterized for potency, selectivity, and functional activity by ligand binding, cell adhesion, and transforming growth factor-β cell activation assays. Precision-cut lung slices generated from lung explants from patients with idiopathic pulmonary fibrosis or bleomycin-challenged mouse lungs were treated with integrin inhibitors or standard-of-care drugs (nintedanib or pirfenidone) and analyzed for changes in fibrotic gene expression or TGF-β signaling. Bleomycin-challenged mice treated with dual α v β 6/α v β 1 integrin inhibitor, PLN-74809, were assessed for changes in pulmonary collagen deposition and Smad3 phosphorylation. Measurements and main results: Inhibition of integrins α v β 6 and α v β 1 was additive in reducing type I collagen gene expression in explanted lung tissue slices from patients with idiopathic pulmonary fibrosis. These data were replicated in fibrotic mouse lung tissue, with no added benefit observed from inhibition of additional α v integrins. Antifibrotic efficacy of dual α v β 6/α v β 1 integrin inhibitor PLN-74809 was confirmed in vivo, where dose-dependent inhibition of pulmonary Smad3 phosphorylation and collagen deposition was observed. PLN-74809 also, more potently, reduced collagen gene expression in fibrotic human and mouse lung slices than clinically relevant concentrations of nintedanib or pirfenidone. Conclusions: In the fibrotic lung, dual inhibition of integrins α v β 6 and α v β 1 offers the optimal approach for blocking fibrogenesis resulting from integrin-mediated activation of transforming growth factor-β.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Effect of αvβ1-selective inhibition (Compound A), αvβ6-selective inhibition (3G9), and dual αvβ6/αvβ1 inhibition (PLN-74809 or Compound A + 3G9) on A COL1A1 mRNA expression and B expression of additional fibrosis-related genes following 7-day culture of PCLSs prepared from lung explants from patients with IPF. Data represent mean (± SD) of 4–5 independent IPF tissues with ≥ 3 slices analyzed per patient tissue. Each symbol within a group represents an individual patient lung, with treatment effects normalized to vehicle. Data in A and B were generated from the same samples. Compound A = 471 nM; 3G9 = 0.5 µg/ml; PLN-74809 = 1.82 µM; TGF-β type I receptor inhibitor (ALK5i [R 268712]) = 1 µM. ALK5i was used as a positive control to confirm TGF-β-driven collagen expression within lung slices. Concentrations selected for integrin inhibitors were ≥ 10 × IC50, determined to inhibit latent TGF-β activation by αvβ1 or αvβ6 in cell-based assays (see Table 1). **P < 0.01 vs DMSO; ****P < 0.0001 vs DMSO. ACTA2: α-smooth muscle actin 2; ALK5i: Activin receptor-like kinase 5 inhibitor; COL1A1: Collagen type I alpha I; COL1A2: Collagen type I alpha II; COL3A1: Collagen type III alpha I; Cpd A: Compound A; CTGF: Connective tissue growth factor; DMSO: Dimethyl sulfoxide; GUSB: Glucuronidase β; IC50: 50% inhibitory concentration; HPRT1: Hypoxanthine phosphoribosyltransferase 1; IPF: Idiopathic pulmonary fibrosis; ITGB6: Integrin subunit β 6; MMP1: Matrix metalloproteinase 1; MMP2: Matrix metalloproteinase 2; MMP7: Matrix metalloproteinase 7; mRNA: Messenger ribonucleic acid; PCLS: Precision-cut lung slice; RPLP0: Ribosomal lateral stalk subunit P0; SD: Standard deviation; SERPINE1: Serpin family E member 1; SNAI1: Snail family transcriptional repressor 1; TGF-β: Transforming growth factor-β; TIMP1: Tissue inhibitor of metalloproteinase 1](https://figures.cochat.ai/paper-figures/1ef1d19ae52d4384b62f5ee061c60b88/dual-inhibition-of-v6-and-v1-reduces-fibrogenesis-in-lung-tissue-explants-from-figure-1.jpg)

![Fig. 3 Mean (± SD) αvβ1 protein levels measured in A lung tissue from healthy subjects vs patients with IPF and B healthy vs fibrotic mouse lung tissue (21 days post-bleomycin challenge). Efficacy of integrin inhibitors of αvβ6 (3G9), αvβ1 (Compound A), or αvβ6/αvβ1 (PLN-74809) at blocking (C) normal human bronchial epithelial cell, D normal human lung fibroblast, and E IPF lung fibroblast adhesion to TGF-β LAP as determined by cell impedance assay. One representative donor cell plotted in (C–E) (mean [± SD] for n = 3 replicate measurements). Pan-αv integrin- and pan-β1 integrin-inhibiting antibodies were also used to demonstrate αvβ1-mediated adhesion of normal and IPF lung fibroblasts to LAP (D, E). Ab: antibody; conc: concentration; Cpd A: Compound A; IPF: idiopathic pulmonary fibrosis; LAP: latency-associated peptide; SD: standard deviation; SMi: small-molecule inhibitor; TGF-β: transforming growth factor-β](https://figures.cochat.ai/paper-figures/46630110cddf4a36bc7f398716e92ae4/dual-inhibition-of-v6-and-v1-reduces-fibrogenesis-in-lung-tissue-explants-from-figure-3.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PDE4A, B and D are expressed in human lung fibroblasts, with PDE4B knockdown leading to inhibition of cytokines basic FGF and IL-1β and TGF-β and subsequent decreased differentiation into myofibroblasts [113,114].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [114]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Woessner, J. F. (1961) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(61)90291-0 · Cited by 3,840
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Self-citationLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Adams, T. S., Schupp, J. C., Poli, S., Ayaub, E. A., Neumark, N., Ahangari, F., Chu, S. G., Raby, B. A., DeIuliis, G., Januszyk, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba1983 · Cited by 1,420
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Henderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3282 · Cited by 866
Specificity, versatility, and control of TGF-β family signaling
Derynck, R., & Budi, E. H. (2019) · Science Signaling · doi:10.1126/scisignal.aav5183 · Cited by 785
Self-citationAbe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., & Rifkin, D. B. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1042 · Cited by 757
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities
Li, S., Sampson, C., Liu, C., Piao, H., & Liu, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01264-4 · Cited by 190
Reviewing the Regulators of COL1A1
Devos, H., Zoidakis, J., Roubelakis, M. G., Latosinska, A., & Vlahou, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210004 · Cited by 119
Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis
May, J. M., Mitchell, J. A., & Jenkins, G. R. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172058 · Cited by 115
Metadata
- Authors
- Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., Budi, E. H., Hooi, L., Wu, J., Fridlib, M., Martin, S. P., Huang, S., Chen, M., Muñoz, M., Hom, T. F., Wolters, P. J., Desai, T. J., Rock, F., Leftheris, K., Morgans, D. J., Lepist, E.-I., Andre, P., Lefebvre, E. A., & Turner, S. M.
- Affiliations
- Pliant (United States) (US)
- University of California, San Francisco (US)
- Stanford Medicine (US)
- Corresponding author
- Turner, Scott M.
- ORCID
- Venue
- Respiratory Research
- Published
- 2021-10-19
- Volume
- 22
- Issue
- 1
- Pages
- 265-265
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- PMC
- PMC8524858
- OpenAlex
- W3207714802
- Cited by
- 94
- References
- 53
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 24 · 2023: 21 · 2022: 5 · 2021: 1
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Respiratory Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, integrin αvβ6, integrin αvβ1, integrin inhibitors, pulmonary fibrosis, TGF-beta signaling, Smad3 phosphorylation, type I collagen, bleomycin-induced lung fibrosis, nintedanib, pirfenidone, precision-cut lung slices, antifibrotic therapy
- MeSH terms
- Antifibrotic Agents, Collagen Type I, alpha 1 Chain, Animals, Bleomycin, Cell Line, Disease Models, Animal, Epithelial Cells, Fibroblasts, Humans, Lung, Mice, Inbred C57BL, Phosphorylation, Signal Transduction, Coculture Techniques, Receptors, Vitronectin, Integrin alpha6beta1, Mice, Smad3 Protein, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. https://app.cochat.ai/papers/10.1186/s12931-021-01863-0
- The paper
- Decaris, M. L., Schaub, J. R., Chen, C., Cha, J., Lee, G. G., Rexhepaj, M., Ho, S. S., Rao, V., Marlow, M. M., Kotak, P., Budi, E. H., Hooi, L., Wu, J., Fridlib, M., Martin, S. P., Huang, S., Chen, M., Muñoz, M., Hom, T. F., . . . Turner, S. M. (2021). Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respiratory Research. https://doi.org/10.1186/s12931-021-01863-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.